Alzheimer's drug candidate tracked in healthy brains

NCT ID NCT06454721

Completed Knowledge-focused Sponsor: Biogen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tested a small, radioactive dose of BIIB080, an experimental Alzheimer's drug, in 5 healthy adults to see how it spreads in the brain and spinal cord. Researchers used PET scans to track the drug after a single injection into the spinal fluid. The main goal was to understand distribution and safety, not to treat any condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BIIB080 (a drug being studied for Alzheimer's disease)
What this could lead to: If successful, this study could help researchers understand how BIIB080 reaches the brain, which may guide future trials for Alzheimer's treatment.
What could go wrong: This is a very early, small study in only 5 healthy volunteers, not patients. It focuses on imaging and safety, not on treating any disease, so it may not lead directly to a therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

UC Davis

Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.